Roundtable Discussion; The Future of Mineral Sands. Watch the video here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
Looks like more buying on the strength of the article now that it has hit the paper version released over the weekend.
GLA
Thanks for the link - I expected ST to tip IHC again for good reason - Recent results were excellent and share price had fallen back 30% on general market malaise (tech stocks USA overrated, inflation, Ukraine etc) so offers rich picking for most private investors. I've picked up some more this morning. Bargain at these levels compared to year high 150p.
After market close.
https://www.investorschronicle.co.uk/ideas/2022/02/22/hunting-down-lowly-rated-tech-plays/
GLA
Agreed - you can buy at 105p, that 30% lower than year high price of 150p.
Revenue up 10.9% v a very strong 2020 when one off ventillators were included in the figures.
On top of that, RNS earlier this week that IHC picked up a £1.0m contract wind from Egypt at start of FY2022.
Good news all round and this is real hidden gem.
Share price will take off when the herd get told its a good company and cheap at current price.
In the meantime, fill yer boots!
blimey,looks cheap aswell,on the 3 month
https://www.proactiveinvestors.co.uk/companies/news/974366/inspiration-healthcare-surges-after-raising-guidance-974366.html
Despite the prior year having a one-off rise of £7.3mn, due to covid related revenue, this year they really knocked the ball out of the park.
Excellent performance by the company.
Inspiration Healthcare Group plc (AIM: IHC), the global medical technology company, is pleased to announce that, following the close of the financial year, the Group is expecting to exceed market expectations and to report Group revenues for the financial year ended 31 January 2022 of approximately £41.0 million representing an increase of 10.9% compared to the prior financial year. Adjusted EBITDA* is expected to be not less than £6.2 million, representing growth of 10.5% over the prior financial year, which includes a one-off receipt of £0.2 million. Operating profit is similarly ahead of market expectations.
Cont'd
Simon T
13/10/21
True, annual cash profits are expected to be flat at £5.6m on revenue of £40.6m year on year, but the prior year’s result included £7.3m of one-off Covid-19 related ventilator orders. Strip these out, and house broker Cenkos Securities pencils in 7 per cent revenue growth in the second half, a healthy underlying trend that is not yet fully priced in an enterprise valuation of £75m, or 13.4 times cash profits, after factoring in net cash of £8.6m (12.6p a share). That’s a hefty ratings discount to neonatal medtech peers, Natus Medical (41 times) and Fisher & Paykel Healthcare (23 times).
Simon T
13/10/21
First-half adjusted operating profit up 22 per cent to £2.6m on 47 per cent higher revenue of £20.9m
Analysts upgrade full-year operating profit forecasts by 12 per cent to £3.5m
Integration of SLE acquisition almost complete
Crawley-based Inspiration Healthcare (IHC:123p), a fully integrated medical technology company with a strong focus on the high-growth neonatal intensive care market, has prompted analysts to upgrade their earnings estimates yet again. Last summer’s acquisition of SLE, a designer and maker of ventilators for neonatal intensive care, has been the driver.
That’s because SLE has not only enlarged the group’s global distribution network – 90 per cent of SLE’s sales are export orders with a strong focus on China, Japan, India and the Middle East – but is creating cross-selling opportunities, too. For example, by bundling consumable breathing circuits with the sale of SLE’s ventilators, and expanding market penetration into a larger installed ventilator and consumable customer base, Inspiration can introduce its breathing circuits to new customers who have been using rival products. In the six months to 31 July 2021, the group won an order worth £350,000 for its own brand Viomedex circuits from an SLE distributor in the Middle East.
Inspiration also received regulatory approval in Japan and China for its enhanced top-of-the-range SLE6000 neonatal ventilator that includes features such as enhanced High Frequency Oscillatory Ventilation (designed for use with critically ill infants) and the OxyGenie ® patented oxygen control algorithm (helps maintain infants at their targeted oxygen saturation levels). This led to a significant number of new orders in both countries, and has raised the profile of the group’s neonatal ventilator portfolio internationally.
In the UK, Inspiration’s AlphaCore patient warming system is proving very popular – sales more than doubled year on year – for the prevention of inadvertent hypothermia in neonatal, paediatric and perioperative environments. The benefits of warming are undeniable, such as improved morbidity and mortality, lower infection rates, reduced blood loss and less time in recovery.
The greater focus on higher-margin branded products – 55 per cent of the sales mix, up from 20 per cent in the first half of 2020 – is helping to drive up gross margin (from 41.4 per cent to 52.5 per cent) despite input cost pressures, which are being managed well. The combination of strong organic growth, a robust order book and increased demand across the entire group led to 12 per cent operating profit upgrades for the full year.
Great news on the Egyptian order. Good news was completely diluted by the russian vs ukraine affair.
Reasonably priced at current levels.
TU expected very shortly. Should be a positive one. Hopefully a positive thumbs up by Simon T as well would be nice too.
It’s probably Premier Milton reducing their massive holding again. If you look back over the last 6 months the share price is very volatile. I think this is an excellent company and so I’ve taken the opportunity to increase my holdings.
There has been systematic share dumping by someone. 10k every 15 secs for approx 120,000 shares. Not sure why but to me that's why the sp has tanked.
SP dropping like a stone, anyone know why?
Hi, this has been highly recommended by Simon Thompson of investors chronicle
IHC shares rose strongly from start of trading today. I presume another 'Share Tip', if so from what source? Otherwise likely reason for the renewed buying interest?
Have had a good run with this company >100% plus dividends. Waiting on interim reports before making any further decisions, but to date I think this business is very well run and seems to be coming together. They really stress their distribution network, which must have significant, but hard to recognise, value. Recent update says H1 47% this time last year (which would have had some covid influence) which puts revenues c21-22m. If they manage the same sales H2 that would be around 42-44m£, which still represent 20% year on year revenue growth. Hopefully they continue with progressive dividend. It looks like the (loss of) the revenue impact of ventilators to the UK covid effort, which I think was around 7-8m, is not being felt at all. I wonder if they will look at more acquisitions.
Reached the £100m milestone yesterday.
Big Chinese order............
"Released 07:00:11 17 May 2021
RNS Number : 7508Y
Inspiration Healthcare Group PLC
17 May 2021
Inspiration Healthcare Group plc
("Inspiration Healthcare", the "Company" or the "Group")
£1.25m Ventilator Order received from China
Inspiration Healthcare Group plc (AIM: IHC), the global medical technology company, is pleased to announce that its wholly owned subsidiary SLE Ltd, which was acquired in July 2020, has received an order worth over £1.25 million to supply ventilators to China which have been sold through its Chinese distributor and which are to be delivered within the next three months.
This new order follows on from the regulatory approval received from the Chinese National Medical Products Administration (NMPA) announced on 21 April 2021 for SLE's top of the range SLE6000 model and is in addition to the order announced at that time, whose value totalled approximately £250,000.
Neil Campbell, Chief Executive Officer, commented:
"We are delighted to be making such strong progress in China within such a short space of time since receiving regulatory approval and this new order certainly helps to strengthen the outlook for the Group going forward. As I have stated previously, China represents a significant growth opportunity and, whilst this order does not change our expected outcome for the year, it is another boost to our confidence as we continue to develop Inspiration Healthcare's position in this important market".
Am I right in thinking that the recent episodes of 'Baby Surgeons: Delivering Miracles from St Georges (TV Channel 4) may be a factor behind the continuing uptick in our shares?
Crawley-based Inspiration Healthcare (IHC:120p), a fully integrated medical technology company with a strong focus on the high-growth neonatal intensive care market, has posted a major earnings beat on all levels.With the company's gross margin five percentage points higher than Cenkos Securities 43.6 per cent forecast, and annual revenues more than doubling to £37m, gross margin of £18m was £2.1m above analysts' estimates and operating profit of £4.3m was almost 50 per cent higher, too. Adjusted earnings per share (EPS) of 6.9p increased 90 per cent year on year, and net cash of £10.7m (15p a share) was almost double forecasts. Last summer's acquisition of SLE, a designer and maker of ventilators for neonatal intensive care, contributed £9.4m to revenue and there were £7.3m of one-off Covid-19 ventilators orders, too, but underlying revenue still increased 14 per cent. There is every reason to expect the positive trend to continue.In the past seven weeks, the company has received regulatory approval in Japan and China for its enhanced top-of-the-range SLE6000 neonatal ventilator that includes features such as enhanced High Frequency Oscillatory Ventilation (designed for use with critically ill infants) and the OxyGenie ® patented oxygen control algorithm (helps maintain infants at their targeted oxygen saturation levels). The higher-margin product has already received £650,000 of orders and chief executive Neil Campbell says that the two territories generated £2.8m-worth of orders with the old model, suggesting decent growth to come from the current base. SLE received a Queens Award for Enterprise this week in recognition of its work in developing an infant ventilator with the OxyGenie closed-loop software algorithm. It can only help boost sales.Sensibly, Inspiration is investing £2m in new facilities which will be operational this autumn to support additional growth capacity. The company is also making progress with its patented non-invasive, non-pharmaceutical respiratory device for apnoea of prematurity, aiming to sell it next year into a target market affecting 1.5m babies annually in the US, Europe and Japan.I suggested buying the shares, at 75p, last autumn (Alpha Research: 'Profit from a medical technology winner', 27 October 2020), and on an enterprise valuation of 12.5 times cash profit estimates, I see ample upside to my 150p target. Buy. Me now - I think this could be over 200 soon
There were around 79 trades in our shares yesterday(4th May) . Anyone able to identify who or what led to this renewed interest? For example was it comment from Simon Thompson again or a new source?
Yes and still doing it - quietly and slowly rising!
Quietly getting on with it, releasing solid results and updates and the share price slowly moving north.
I bought at 52 week low, and nothing but positive news since. Great stuff. Great contact wins!